Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer

INTRODUCTION: Recent developments in immune checkpoint inhibitors (ICIs) have improved the treatment outcomes of esophageal cancer (EC); however, it may initiate immune-related adverse events (irAEs) in some patients. The ICIs’ therapeutic efficacy is associated with irAEs in patients with non-small...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Wenru, Yang, Linlin, Fan, Bingjie, Zou, Bing, Duan, Yanan, Li, Butuo, Wang, Linlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554876/
https://www.ncbi.nlm.nih.gov/pubmed/36248782
http://dx.doi.org/10.3389/fimmu.2022.931429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554876/
https://www.ncbi.nlm.nih.gov/pubmed/36248782
http://dx.doi.org/10.3389/fimmu.2022.931429

Ejemplares similares